Illumina, Inc. (NASDAQ:ILMN) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 1.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 148,723 shares of the life sciences company's stock after selling 2,900 shares during the period. New York State Teachers Retirement System owned approximately 0.09% of Illumina worth $19,874,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Chevy Chase Trust Holdings LLC grew its position in shares of Illumina by 8.3% during the 4th quarter. Chevy Chase Trust Holdings LLC now owns 526,414 shares of the life sciences company's stock valued at $70,345,000 after acquiring an additional 40,219 shares during the period. V Square Quantitative Management LLC grew its position in shares of Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company's stock valued at $52,000 after acquiring an additional 132 shares during the period. Vontobel Holding Ltd. grew its position in shares of Illumina by 12.5% during the 4th quarter. Vontobel Holding Ltd. now owns 5,941 shares of the life sciences company's stock valued at $794,000 after acquiring an additional 660 shares during the period. Asset Management One Co. Ltd. grew its position in shares of Illumina by 9.4% during the 4th quarter. Asset Management One Co. Ltd. now owns 97,042 shares of the life sciences company's stock valued at $13,127,000 after acquiring an additional 8,299 shares during the period. Finally, Tranquility Partners LLC grew its position in shares of Illumina by 107.6% during the 4th quarter. Tranquility Partners LLC now owns 3,656 shares of the life sciences company's stock valued at $489,000 after acquiring an additional 1,895 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Down 5.6 %

ILMN stock traded down $5.80 during midday trading on Thursday, hitting $97.20. The stock had a trading volume of 5,941,966 shares, compared to its average volume of 2,542,587. The firm has a market cap of $15.40 billion, a PE ratio of -12.66, a price-to-earnings-growth ratio of 1.67 and a beta of 1.10. The company's 50-day moving average price is $129.96 and its 200 day moving average price is $134.41. Illumina, Inc. has a 12-month low of $95.23 and a 12-month high of $156.66. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. TD Cowen cut Illumina from a "buy" rating to a "hold" rating and dropped their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Royal Bank of Canada lowered their price objective on Illumina from $250.00 to $247.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Citigroup cut Illumina from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $190.00 to $165.00 in a report on Wednesday, December 11th. Stephens lifted their price objective on Illumina from $170.00 to $184.00 and gave the stock an "overweight" rating in a report on Tuesday, November 12th. Finally, Guggenheim lowered their price objective on Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.